|Title:||A Two Year Review Of Anti-Fibrotic Medication For the Treatment of Idopathic Pulmonary Fibrosis In St James’s Hospital|
|Author(s):||R Kennedy, L Dolan, C Gray, K Devenney, P Nadarajan|
|Institution:||St James's Hospital|
|Poster:||Click to view poster|
|Abstract:||Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing lung disease with high mortality¹. Two antifibrotic (AF) drugs Pirfenidone and Nintedanib have been licenced in Idiopathic Pulmonary Fibrosis (IPF) for use in Ireland since 2015, with the aim of slowing disease progression. However, they are associated with side-effects which can affect quality of life and result in discontinuation.|
We performed a retrospective analysis of all patients with IPF commenced on AF’s at our site between 2017 and 2019, to determine reasons for treatment discontinuation and most common side effects.
Twenty-eight patients (mean age 73 year ± SD, 39.2% female) were included with 42% (n=12) commenced on Nintedanib and 57% (n=16) commenced on Pirfenidone. During this 2-year period, 25% (n=7) had treatment stopped (2 diarrhoea, 2 nausea & vomiting, 1 skin reaction 1 died), 21.4% (n=6) had their treatment switched and 53.6% (n=15) did not require a change to treatment. 66% (n=4) of those patients that required a switch of their treatment reported N&V.
Side effects are common with AF treatment, further research will ascertain whether nursing interventions may reduce this rate.